重组人脑利钠肽联合BiPAP在治疗重症急性心力衰竭患者中的应用价值  

Recombinant Human Brain Natriuretic Peptide in Diagnosing Severe Joint BiPAP Therapy for Patients with Acute Heart Failure

作　　者：梁明[1] 陈星[1] 丛云峰[1] 

机构地区：[1]黑龙江省医院南岗院区急救中心,黑龙江哈尔滨150000

出　　处：《中外医疗》2016年第20期103-104,共2页China & Foreign Medical Treatment

摘　　要：目的探究重组人脑利钠肽联合BiPAP在治疗重症急性心力衰竭患者中的应用价值。方法整群选取该院2015年2月1日—2016年3月1日收治的重症心力衰竭的患者54例,随机分为联合组和对照组,分别进行重组人脑利钠肽联合BiPAP治疗以及单纯BiPAP治疗,比较两组的治疗效果以及NT-proBNP指标等。结果两组患者在治疗前、治疗后以及NT-proBNP指标的差值方面上,差异有统计学意义(P<0.05);联合组、对照组治疗有效率分别为96.30%、70.37%,差异有统计学意义(P<0.05)。结论BiPAP联合rhBNP治疗重症急性心力衰竭患者,其可以高效改善患者的心力衰竭症状,同时降低患者的NT-proBNP指标,值得在临床推广。Objective To explore severe value in the recombinant human brain natriuretic peptide combined with BiPAP in the treatment of patients with acute heart failure.Methods Group selection 54 patients with severe heart failure chosen in the hospifal from February1,2015 to March,2016,randomly divided into combination group and control group, respectively, for recombinant human brain natriuretic peptide combined with BiPAP BiPAP therapy and simple treatment, therapeutic ef-fects were compared and NT-proBNP indicators. Results Two groups of patients before treatment, and the difference be-tween the index terms of NT-proBNP after treatment, the difference was statistically significant （P〈0.05）; the combination group, the control group response rate was 96.30%, 70.37% respectively, the difference statistically significance （P〈0.05）. Conclusion BiPAP United rhBNP treatment of severe acute heart failure, which can effectively improve the symptoms of heart failure patients and reduce the patient＇s NT-proBNP indicator, worthy of promotion.

关 键 词：重组人脑利钠肽 双水平正压 心力衰竭 

分 类 号：R459.7[医药卫生—急诊医学]